Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 40
Filter
Add more filters










Publication year range
1.
Cell Prolif ; 46(2): 183-92, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23510473

ABSTRACT

OBJECTIVES: Restorative properties of medicinal plants such as Genista sessilifolia DC. have often been suggested to occur, in epidemiological studies. However, full characterization of effective principles responsible for this action has never previously been performed. Here, we have characterized G. sessilifolia's anti-cancer effects and identified the chemical components involved in this anti-tumour action. MATERIALS AND METHODS: Cell cycle, apoptosis, necrosis, differentiation analyses, high-performance liquid chromatography, western blotting, RNA extraction, real-time PCR and primers have all been observed/used in the study. RESULTS: We report that G. sessilifolia methanol extract has anti-cancer activity on solid and haematological cancer cells. G. sessilifolia extract's anti-proliferative action is closely bound to induction of apoptosis, whereas differentiation is only weakly modulated. Analysis of G. sessilifolia extract, by high-performance liquid chromatography, identifies fraction 18-22 as the pertinent component for induction of apoptosis, whereas fractions 11-13 and 27-30 both seem to contribute to differentiation. G. sessilifolia extract induces apoptosis mediated by caspase activation and p21, Rb, p53, Bcl2-associated agonist of cell death (BAD), tumour necrosis factor receptor super-family, member 10 (TRAIL) overexpression and death receptor 5 (DR5). Accordingly, fraction 18-22 inducing apoptosis was able to induce TRAIL. CONCLUSIONS: Our results indicate that G. sessilifolia extract and its fraction 18-22 containing genistin and isoprunetin, were able to induce anti-cancer effects supporting the hypothesis of a pro-apoptotic intrinsic content of this natural medicinal plant.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Apoptosis , Genista/chemistry , Plant Extracts/pharmacology , Antineoplastic Agents, Phytogenic/chemistry , Caspase 8/chemistry , Caspase 8/genetics , Cell Cycle , Cell Differentiation , Cell Proliferation/drug effects , Chemical Fractionation/methods , Chromatography, High Pressure Liquid , Enzyme Activation , Flow Cytometry , Genistein/chemistry , Genistein/isolation & purification , Genistein/pharmacology , Granulocytes/drug effects , Granulocytes/pathology , HeLa Cells , Humans , Isoflavones/chemistry , Isoflavones/isolation & purification , Isoflavones/pharmacology , MCF-7 Cells , Methanol/chemistry , Plant Components, Aerial/chemistry , Plant Extracts/chemistry , Real-Time Polymerase Chain Reaction , Receptors, TNF-Related Apoptosis-Inducing Ligand/chemistry , Receptors, TNF-Related Apoptosis-Inducing Ligand/genetics , TNF-Related Apoptosis-Inducing Ligand/genetics , TNF-Related Apoptosis-Inducing Ligand/metabolism , U937 Cells , bcl-Associated Death Protein/genetics , bcl-Associated Death Protein/metabolism
2.
J Biol Regul Homeost Agents ; 26(1): 67-79, 2012.
Article in English | MEDLINE | ID: mdl-22475098

ABSTRACT

Peripheral arterial disease (PAD) is a chronic condition caused by atherosclerosis and is a severe complication of type 2 diabetes (T2D). We hypothesised that chronic condition of arterial disease engenders inflammation and endothelial damage in response to circulating cytokines released in the blood stream of PAD patients. We explored the levels of circulating cytokines in PAD patients with and without diabetes by multiplex cytokine array compared with non-PAD controls. Serum from PAD patients with or without diabetes showed high levels of VEGF, IFN-gamma, TNF-alpha, MCP-1, and EGF. VEGF levels correlated with TNF-alpha and IFN-gamma, significantly. Endothelial cells (ECs) were exposed to the different altered cytokines to evaluate changes in cell growth, migration and tubule-like formation, displaying impairment on proliferation, migration and tubule formation. Our findings demonstrate that a set of cytokines is significantly increased in the serum of PAD patients. These cytokines act to induce endothelial dysfunction synergistically. VEGF strongly correlated with TNF-alpha and IFN-gamma, opening new therapeutic perspectives.


Subject(s)
Cytokines/blood , Endothelium, Vascular/physiopathology , Peripheral Arterial Disease/blood , Peripheral Arterial Disease/physiopathology , Aged , Aged, 80 and over , Case-Control Studies , Cell Hypoxia , Cell Movement , Cell Proliferation , Chemokine CCL2/blood , Cytokines/pharmacology , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/physiopathology , Endothelium, Vascular/cytology , Epidermal Growth Factor/blood , Female , Human Umbilical Vein Endothelial Cells/drug effects , Humans , Interferon-gamma/blood , Male , Middle Aged , Peripheral Arterial Disease/etiology , Tumor Necrosis Factor-alpha/blood , Vascular Endothelial Growth Factor A/blood
3.
Cell Prolif ; 45(1): 22-31, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22172154

ABSTRACT

OBJECTIVES: Curative properties of medicinal plants such as Psidium guajava L. (Myrtaceae) have often been indicated by epidemiological studies on populations in which these fruits are consumed daily. However, complete characterization of the active principles responsible for this ability has never been performed. Here, we have characterized P. guajava's anti-cancer potential and identified the parts of the fruit involved in its anti-neoplastic action. MATERIALS AND METHODS: We studied morphology of our cells, cell cycle characteristics and apoptosis and performed immunostaining, differentiation and western blot analyses. RESULTS: We report that the P. guajava extract exerted anti-cancer control on both haematological and solid neoplasias. P. guajava extract's anti-tumour properties were found to be tightly bound to induction of apoptosis and differentiation. Use of ex vivo myeloid leukaemia blasts corroborated that P. guajava was able to induce cell death but did not exhibit anti-cancer effects on all malignant cells investigated, indicating selective activity against certain types of tumour. Analyses of P. guajava pulp, peel and seeds identified the pulp as being the most relevant component for causing cell cycle arrest and apoptosis, whereas peel was responsible for causing cell differentiation. P. guajava itself and its pulp-derived extract were found to induce apoptosis accompanied by caspase activation and p16, p21, Fas ligand (FASL TNF super-family, member 6), Bcl-2-associated agonist of cell death (BAD) and tumour necrosis factor receptor super-family, member 10b (DR5), overexpression. CONCLUSIONS: Our findings showed that P. guajava L. extract was able to exert anti-cancer activity on cultures in vitro and ex vivo, supporting the hypothesis of its anti malignant pro-apoptotic modulation.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Apoptosis/drug effects , Cell Differentiation/drug effects , Phytotherapy , Psidium , Caspases/metabolism , Cell Cycle/drug effects , Cell Line, Tumor , Humans , Leukemia, Promyelocytic, Acute/drug therapy , Leukemia, Promyelocytic, Acute/metabolism , Leukemia, Promyelocytic, Acute/pathology , Neoplasm Proteins/metabolism , Plant Extracts/pharmacology , Plants, Medicinal , U937 Cells
4.
J Clin Endocrinol Metab ; 90(7): 4138-44, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15855253

ABSTRACT

OBJECTIVE: In this prospective study, we investigated whether the development of interferon (IFN)-alpha-related autoimmune thyroiditis (IFN-AT) was correlated with the sequential changes of cytokine pattern induced by IFNalpha in the peripheral lymphocytes. PATIENTS AND METHODS: We enrolled 18 hepatitis C virus (HCV)-positive patients who developed IFN-AT, eight patients with euthyroidism [IFN-AT(Eu)] and 10 with thyroid dysfunction [IFN-AT(Dy)]. Twenty HCV-positive patients without IFN-AT acted as control group (Co-HCV+). Intracellular expression of IFNgamma and IL-4 was evaluated by multicolor flow-cytometry analysis in peripheral lymphocytes in vitro stimulated by phorbol-12-myristate-13-acetate (PMA) (25 ng/ml) and ionomycin (1 mug/ml) in presence of monensin (5 microm). RESULTS: At the appearance of thyroid disease, both IFN-AT(Eu) and IFN-AT(Dy) patients showed a significant increase of IFNgamma expression in CD3+CD56+ and CD3-CD56+ cells but not in CD4+ and CD8+ cells. At this time point, IFN-AT(Eu) but not IFN-AT(Dy) patients also showed an increase of IL-4 expression in CD3+CD56+ cells and CD4+ cells. Six months later, IFN-AT(Eu) patients maintained high expression of IL-4 in CD4+ and CD3+CD56+ cells without any further increase in IFNgamma expression. By contrast, IFN-AT(Dy) patients showed an increase of IFNgamma expression in CD4+ and CD8+ cells, with a concomitant decrease of IL-4 expression in CD4+ cells. CONCLUSIONS: Type 2 immune response is activated early and specifically in patients with IFN-AT who remain euthyroid throughout the follow-up. Predominant in patients developing thyroid dysfunction, by contrast, is the type 1 immune response that seems to occur earlier in innate than acquired immune system.


Subject(s)
Interferon-alpha/adverse effects , Thyroiditis, Autoimmune/etiology , Thyroiditis, Autoimmune/immunology , Adult , Female , Humans , Immunity, Innate , Interferon-gamma/biosynthesis , Interleukin-4/biosynthesis , Male , Middle Aged , Th1 Cells/immunology , Th2 Cells/immunology
6.
J Viral Hepat ; 10(4): 266-70, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12823592

ABSTRACT

Mutated p53 acts as a dominant oncogene and alterations in the p53 gene are described in a large number of patients with hepatocellular carcinoma (HCC). It has been demonstrated that hepatitis C virus (HCV)-core protein regulates transcriptionally cellular genes, as well as cell growth and apoptosis. This study was undertaken to evaluate whether p53 may be expressed also in a precocious stage of HCV-related liver damage. We studied p53 expression by immunoluminometric assay on liver samples from 40 patients (M/F 18/ 22, median age 44 years, range 13-64 years) with biopsy-proven HCV-related chronic hepatitis. We considered the following factors: degree of liver damage, liver iron content and HCV-RNA titre. We also evaluated as possible co-factors alcohol and food intake in the last 3 years. p53 was over-expressed in seven of 40 (17.5%) patients. Liver histology documented the presence of unexpected cirrhosis in two patients among the p53 positive subjects. The p53 positive group had a daily ethanol intake significantly higher in respect to that of the p53 negative group (P < 0.05). Alimentary history documented that patients with a p53 over-expression had a lower intake of total calories, monounsaturated fatty acids, vitamin C and riboflavin. Data indicate that p53 over-expression can occur even in initial stages of HCV-related liver disease.


Subject(s)
Genetic Predisposition to Disease , Hepacivirus/genetics , Hepatitis C, Chronic/genetics , Hepatitis C, Chronic/pathology , Tumor Suppressor Protein p53/genetics , Adolescent , Adult , Analysis of Variance , Biopsy, Needle , Case-Control Studies , Chi-Square Distribution , Cohort Studies , DNA, Viral/analysis , Female , Gene Expression Regulation, Viral , Humans , Immunohistochemistry , Male , Middle Aged , Probability , Proto-Oncogene Proteins/genetics , Reference Values , Reverse Transcriptase Polymerase Chain Reaction , Sensitivity and Specificity , Statistics, Nonparametric
7.
Ann N Y Acad Sci ; 963: 329-31, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12095960

ABSTRACT

Helicobacter pylori is a definite carcinogen whose mechanism of action is still unknown. The aim of this work was (1) to determine the presence of p53 protein and related antibodies in patients affected by various gastric pathologies and chronically infected with H. pylori, and (2) to try to discover a test to be used as a marker of a possible switch towards a neoplastic phenotype.


Subject(s)
Cell Transformation, Neoplastic/metabolism , Helicobacter Infections/physiopathology , Helicobacter pylori , Tumor Suppressor Protein p53/metabolism , Antibodies/immunology , Cell Transformation, Neoplastic/immunology , Helicobacter Infections/immunology , Helicobacter Infections/metabolism , Humans , Phenotype , Tumor Suppressor Protein p53/immunology
8.
Mol Med ; 7(8): 552-60, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11591891

ABSTRACT

BACKGROUND: The retinoblastoma-interacting zinc-finger gene RIZ is expressed in two forms (RIZ1 and RIZ2) that differ for the presence near the N-terminus of RIZ1 of a conserved domain, defined PR (PRDI-BF1-RIZ homology), homologous to a similar domain present in other proteins recognized as tumor suppressor gene products. The RIZ1 form is usually absent or expressed at low levels in tumor cells, whereas RIZ2 is frequently expressed. We investigated a possible involvement of RIZ1 in differentiation control using a myeloid cell maturation model that is easily modulated by retinoids and other agents. MATERIALS AND METHODS: HL60 or NB4 cell lines or patients' leukemic promyelocytes were treated with all- trans -retinoic acid or other agents to induce differentiation. RIZ gene expression was determined with reverse transcriptase polymerase chain reaction (RT-PCR) and RNase protection assay. Immunocytochemistry was performed to assess variation of the intracellular distribution of RIZ protein on all- trans-retinoic acid treatment. Forced expression of RIZ1 protein was obtained with a recombinant adenovirus containing RIZ1 cDNA. RESULTS: Treatment with retinoic acid induced a selective expression of RIZ1 in HL60 cell line. Retinoic acid effect was maximal at 7 days and correlated to the granulocytic differentiation of cells. A similar effect was obtained in retinoic acid-sensitive NB4 cell line or in patients' leukemic promyelocytes, but not in the retinoic acid-resistant cell line NB4.007/6 or in the U937 cell line. Selective expression of RIZ1 was also induced by 12-O-tetradecanoyl-phorbol-13-acetate in the U937 and HL60 cell lines and by 1,25-dihydroxyvitamin D(3) only in HL60 cells. In HL60 cells, RIZ1 was also induced by activation of a retinoid alpha receptor-independent maturation pathway based on retinoid X receptor agonist and protein kinase A synergism. In addition, retinoic acid produced a redistribution of the antigen within the nucleus in these cells. Forced expression of RIZ1 protein induced growth arrest and death of HL60 cells. CONCLUSIONS: The correlation between the selective expression of RIZ1 induced by retinoic acid, 12-O-tetradecanoyl-phorbol-13-acetate, or 1,25-dihydroxyvitamin D(3) and differentiation suggested that RIZ protein was involved in myeloid cell differentiation induced by these agents.


Subject(s)
Cell Differentiation/physiology , DNA-Binding Proteins , Myeloid Cells/physiology , Nuclear Proteins/metabolism , Transcription Factors , Adenosine Monophosphate/analogs & derivatives , Adenoviridae/metabolism , Antineoplastic Agents/pharmacology , Benzoates/pharmacology , Cells, Cultured , Histone-Lysine N-Methyltransferase , Humans , Immunoblotting , Immunohistochemistry , Myeloid Cells/cytology , Myeloid Cells/drug effects , Nuclear Proteins/genetics , Retinoblastoma Protein/genetics , Retinoblastoma Protein/metabolism , Retinoids/pharmacology , Tretinoin/pharmacology , Zinc Fingers/genetics
9.
Lung Cancer ; 33(2-3): 163-9, 2001.
Article in English | MEDLINE | ID: mdl-11551411

ABSTRACT

As reported earlier, p53 antibodies are detected in the sera of patients with different types of cancer, including lung cancer. In contrast, in the serum of healthy subjects the presence of anti-p53 antibodies is extremely rare. We collected the venous blood samples of 109 patients affected with lung cancer (LC): 57 patients (46 M, 11 F) with non-small-cell carcinoma (NSCLC), 52 others (40 M, 12 F) with small-cell carcinoma (SCLC). Serum p53 antibodies were assayed using ELISA method and all positive sera were confirmed by Western-blot method. In addition, using IRMA methods we assayed serum CEA, TPA, CYFRA21-1 and NSE. Serum p53Ab are detectable (p53Ab-positive) in 35/109 (32.1%) patients with lung cancer. About 17/57 (29.8%) patients affected with NSCLC and 18/52 (34.6%) with SCLC were p53Ab-positive. CEA, TPA, CYFRA21-1 and NSE sensitivity in LC patients (NSCLC+SCLC) is 50.5%, 58.7%, 42.2%, 35.8%, respectively. The lower sensitivity (32.1%) of serum p53Ab is connected with the higher specificity and diagnostic accuracy (100% and 69%, respectively). Out of 35 patients p53Ab-positive, five (14.3%) exhibit only serum p53Ab, while serum values of the established tumor markers were lower than cut-off. Serum p53Ab assessment is a simple and a low-cost assay with a good specificity and diagnostic accuracy that in LC patients can be used at least in association with established tumor markers.


Subject(s)
Antibodies, Neoplasm/blood , Antigens, Neoplasm/immunology , Biomarkers, Tumor/blood , Carcinoma, Non-Small-Cell Lung/immunology , Carcinoma, Small Cell/immunology , Lung Neoplasms/immunology , Tumor Suppressor Protein p53/immunology , Aged , Aged, 80 and over , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Neoplasm Staging , Sensitivity and Specificity
10.
J Pediatr Endocrinol Metab ; 14(9): 1635-9, 2001.
Article in English | MEDLINE | ID: mdl-11795654

ABSTRACT

OBJECTIVE: It is rare that manufacturers report age-related FT3, FT4 and TSH normal ranges in healthy children. STUDY DESIGN: Using a solid phase time-resolved fluoroimmunometric method, we determined serum FT3, FT4 and TSH in 3,360 healthy children, age 2-16 years, that we grouped into two age ranges (2-7 yr and 9-16 yr). RESULTS: Boys' and girls' mean serum thyroid hormone values substantially overlap in all age groups. In the age range 2-7 yr, FT3, FT4 and TSH values were 0.10-0.67 ng/dl (mean 0.37 ng/dl), range 0.45-2.29 ng/dl (mean 1.18 ng/dl) and 0.10-5.9 microU/ml (mean 2.2 microU/ml), respectively. In the age range 9-16 yr, FT3, FT4 and TSH values were 0.11-0.53 ng/dl (mean 0.35 ng/dl), 0.69-1.69 ng/dl (mean 1.07 ng/dl) and 0.20-6.1 microU/ml (mean 2.3 pU/ml), respectively. CONCLUSION: Our results represent a useful set of reference values in children and can help physicians in the management of thyroid diseases.


Subject(s)
Thyrotropin/blood , Thyroxine/blood , Triiodothyronine/blood , Adolescent , Aging/blood , Child , Child, Preschool , Female , Humans , Male , Osmolar Concentration , Reference Values
12.
Cancer Res ; 60(10): 2594-7, 2000 May 15.
Article in English | MEDLINE | ID: mdl-10825127

ABSTRACT

Estrogen treatment of MCF-7 cells grown in serum-free medium induced a modification of the intracellular distribution of p53 protein. Western blot analysis and immunofluorescence staining showed that p53 was localized in the nucleus of untreated cell and that after 48 h of hormone treatment, it was mostly localized in the cytoplasm. This effect was blocked by the antiestrogen ICI182,780. Intracellular redistribution of p53 was correlated to a reduced expression of the WAF1/CIP1 gene product and to the presence of degradation fragments of p53 in the cytosol. Estradiol treatment prevented the growth inhibition induced by oligonucleotide transfection, simulating DNA damage. This observation indicated that the wild-type p53 gene product present in the MCF-7 cell could be inactivated by estradiol through nuclear exclusion to permit the cyclin-dependent phosphorylation events leading to the G1-S transition. In addition, the estradiol-induced inactivation of p53 could be involved in the tumorigenesis of estrogen-dependent neoplasm.


Subject(s)
Breast Neoplasms/metabolism , Estradiol/metabolism , Tumor Suppressor Protein p53/antagonists & inhibitors , Blotting, Western , Cyclin-Dependent Kinase Inhibitor p21 , Cyclins/biosynthesis , DNA Damage , Electrophoresis, Polyacrylamide Gel , Estradiol/analogs & derivatives , Estradiol/pharmacology , Estrogen Antagonists/pharmacology , Female , Fulvestrant , G1 Phase , Humans , Immunohistochemistry , S Phase , Transfection , Tumor Cells, Cultured
13.
Proc Natl Acad Sci U S A ; 97(7): 3130-5, 2000 Mar 28.
Article in English | MEDLINE | ID: mdl-10706618

ABSTRACT

Co-immunoprecipitation experiments in cell extract from cultured cells or target tissues indicated that estrogen receptor was complexed with the retinoblastoma binding protein RIZ in a ligand-dependent manner. Mapping of interaction sites indicated that in both proteins the same regions and motifs responsible for the interaction of transcriptional co-activator and nuclear receptors were involved. In cultured cells, estradiol induced a redistribution of RIZ protein within the nucleus and in the cytoplasm. A similar effect was produced in vivo, in prepuberal rat endometrium, by administration of a physiological dose of estradiol. Therefore, RIZ protein could be a specific effector of estrogen action downstream of the hormone-receptor interaction, presumably involved in proliferation control.


Subject(s)
DNA-Binding Proteins , Estrogens/physiology , Nuclear Proteins/metabolism , Transcription Factors , Zinc Fingers , Base Sequence , Cell Line , DNA Primers , Histone-Lysine N-Methyltransferase , Humans , Receptors, Estrogen/metabolism
15.
Biochem Biophys Res Commun ; 264(3): 983-9, 1999 Nov 02.
Article in English | MEDLINE | ID: mdl-10544042

ABSTRACT

Double-stranded DNA fragments were selected from a random pool by repeated cycles of estrogen receptor-specific immunoprecipitation in the presence of a nuclear extract and PCR amplification (cyclic amplification and selection of target, CAST, for multiple elements). Fragments were cloned and sequence analysis indicated the 5-nucleotide word TTGGC was the most recurrent sequence unrelated to the known estrogen responsive element. Screening a HeLa cell expression library with a probe designed with multiple repeats of this sequence resulted in the identification of a 1700-aa protein showing a complete homology with the product of the human retinoblastoma-interacting zinc-finger gene RIZ. In transfection experiments, RIZ protein was able to bestow estrogen inducibility to a promoter containing an incomplete estrogen responsive element and a TTGGC motif. RIZ protein present in MCF-7 cell nuclear extract retarded the TTGGC-containing probe in an EMSA. Estrogen receptor was co-immunoprecipitated from MCF-7 cell extract by antibodies to RIZ protein and vice versa, thus indicating an existing interaction between these two proteins.


Subject(s)
DNA-Binding Proteins/genetics , Nuclear Proteins/genetics , Receptors, Estrogen/genetics , Transcription Factors , Base Sequence , DNA-Binding Proteins/metabolism , HeLa Cells , Histone-Lysine N-Methyltransferase , Humans , Molecular Sequence Data , Nuclear Proteins/metabolism , Receptors, Estrogen/metabolism , Sequence Analysis , Transfection , Zinc Fingers
16.
Tumori ; 85(1): 32-4, 1999.
Article in English | MEDLINE | ID: mdl-10228494

ABSTRACT

AIMS AND BACKGROUND: E-cadherin, also known as uvomorulin or cell-CAM 120/80, is one of the subclasses of cadherins, CA(2+)-dependent cell adhesion molecules. Several recent studies have suggested that loss of E-cadherin may be associated with tumor progression, such as in lung, gastric, hepatocellular, breast and prostatic carcinoma. Assessment of E-cadherin serum levels in lung cancer showed a relation to histologic type. METHODS AND STUDY DESIGN: Using an enzyme immunoassay, we determined E-cadherin serum levels in 79 patients affected with lung cancer (stage I-IV), 9 patients with breast cancer, 23 patients with different benign diseases, and 20 healthy patients. RESULTS: At a specificity level of 90%, E-cadherin diagnostic sensitivity was 66.6%, 47.6% and 43.7% in patients affected with squamous cell carcinoma, small cell carcinoma and adenocarcinoma, respectively. CONCLUSIONS: Preliminary results suggest the use of serum E-cadherin as a prospective tumor marker.


Subject(s)
Cadherins/blood , Carcinoma, Non-Small-Cell Lung/blood , Carcinoma, Small Cell/blood , Lung Neoplasms/blood , Lung Neoplasms/pathology , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Small Cell/pathology , Female , Humans , Male , Neoplasm Staging , Sensitivity and Specificity
18.
J Cell Biol ; 141(6): 1301-10, 1998 Jun 15.
Article in English | MEDLINE | ID: mdl-9628887

ABSTRACT

A 104-kD protein was coimmunoprecipitated with the estrogen receptor from the flowtrough of a phosphocellulose chromatography of MCF-7 cell nuclear extract. mAbs to this protein identified several cDNA clones coding for the human 104-kD major vault protein. Vaults are large ribonucleoprotein particles of unknown function present in all eukaryotic cells. They have a complex morphology, including several small molecules of RNA, but a single protein species, the major vault protein, accounts for >70% of their mass. Their shape is reminiscent of the nucleopore central plug, but no proteins of known function have been described to interact with them. Western blot analysis of vaults purified on sucrose gradient showed the presence of estrogen receptor co-migrating with the vault peak. The AER317 antibody to estrogen receptor coimmunoprecipitated the major vault protein and the vault RNA also in the 20,000 g supernatant fraction. Reconstitution experiments of estrogen receptor fragments with the major vault protein mapped the site of the interaction between amino acids 241 and 280 of human estrogen receptor, where the nuclear localization signal sequences are located. Estradiol treatment of cells increased the amount of major vault protein present in the nuclear extract and coimmunoprecipitated with estrogen receptor, whereas the anti-estrogen ICI182,780 had no effect. The hormone-dependent interaction of vaults with estrogen receptor was reproducible in vitro and was prevented by sodium molybdate. Antibodies to progesterone and glucocorticoid receptors were able to coimmunoprecipitate the major vault protein. The association of nuclear receptors with vaults could be related to their intracellular traffic.


Subject(s)
Breast Neoplasms/metabolism , Neoplasm Proteins/metabolism , Receptors, Estrogen/metabolism , Ribonucleoproteins/metabolism , Vault Ribonucleoprotein Particles , Animals , Estradiol/pharmacology , Estrogens/metabolism , Estrogens/pharmacology , Female , HeLa Cells , Humans , Mice , Mice, Inbred BALB C , Neoplasm Proteins/genetics , Precipitin Tests , RNA , Receptors, Cytoplasmic and Nuclear/metabolism , Receptors, Estrogen/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Ribonucleoproteins/genetics , Tumor Cells, Cultured
19.
Hum Mol Genet ; 6(4): 601-7, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9097966

ABSTRACT

The BIO14.6 hamster is a widely used model for autosomal recessive cardiomyopathy. These animals die prematurely from progressive myocardial necrosis and heart failure. The primary genetic defect leading to the cardiomyopathy is still unknown. Recently, a genetic linkage map localized the cardiomyopathy locus on hamster chromosome 9qa2.1-b1, excluding several candidate genes. We now demonstrate that the cardiomyopathy results from a mutation in the delta-sarcoglycan gene that maps to the disease locus. This mutation was completely coincident with the disease in backcross and F2 pedigrees. This constitutes the first animal model identified for human sarcoglycan disorders.


Subject(s)
Cardiomyopathies/genetics , Cytoskeletal Proteins/genetics , Membrane Glycoproteins/genetics , Amino Acid Sequence , Animals , Base Sequence , Blotting, Southern , Blotting, Western , Chromosome Mapping , Cricetinae , Cytoskeletal Proteins/chemistry , Cytoskeletal Proteins/deficiency , Disease Models, Animal , Female , Genetic Linkage , Humans , In Situ Hybridization, Fluorescence , Male , Membrane Glycoproteins/chemistry , Membrane Glycoproteins/deficiency , Mesocricetus , Molecular Sequence Data , Mutation/genetics , Polymerase Chain Reaction , Sarcoglycans , Sequence Deletion , Sequence Homology, Amino Acid
20.
Tumori ; 83(2): 594-8, 1997.
Article in English | MEDLINE | ID: mdl-9226027

ABSTRACT

An immunoradiometric method of the second generation (IR-MA II) is widely used to determine CA125 serum levels. In this study we have evaluated the performance characteristics of a commercially available IRMA CA125 II (Byk-Gulden, Sangtec Diagnostica). The CA125 serum levels were determined in several groups of patients (healthy women, pregnant women, subjects affected by benign and malignant ovarian cancer, patients with liver diseases) with two IRMAs CA125 II (Byk-Gulden, Sangtec Diagnostica and Centocor, Diagnostic Division) and IRMA CA125 I (Byk-Gulden, Sangtec Diagnostica). Our results show a good analytic performance of IRMA CA125 II (Byk-Gulden, Sangtec Diagnostica), a good correlation between IRMAs CA125 II (Byk-Gulden, Sangtec Diagnostica and Centocor, Diagnostic Division), but an unacceptable correlation between IRMAs CA125 II (Byk-Gulden, Sangtec Diagnostica and Centocor, Diagnostic Division) and IRMA CA125 I. A statistically significant difference was observed comparing the values obtained with both IRMAs CA125 II and IRMA CA125 I in the groups of patients. In contrast no statistically significant difference was observed when we compared the values obtained with IRMA CA125 II (Byk-Gulden, Sangtec Diagnostica) and IRMA CA125 II (Centocor, Diagnostic Division). CA125 serum values obtained with the second-generation kits were different from those obtained with the first-generation one; consequently, it is important, especially in the follow-up of cancer patients, that CA125 serum values be obtained with kits of the same generation. Our data seem to suggest the use of second-generation kits to determine CA125 serum levels.


Subject(s)
CA-125 Antigen/blood , Immunoradiometric Assay , Liver Diseases/immunology , Ovarian Diseases/immunology , Ovarian Neoplasms/immunology , Pregnancy/immunology , Female , Humans , Reference Values
SELECTION OF CITATIONS
SEARCH DETAIL
...